NCT00111475View on ClinicalTrials.gov

Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 1, 2002

Primary Completion Date

June 17, 2004

Study Completion Date

June 17, 2004

Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
DRUG

Romiplostim

Administered by subcutaneous injection

DRUG

Placebo

Administered by subcutaneous injection

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY